Curative effect of stereotactic radiotherapy combined with TACE for patients with hepatic metastases of colorectal cancer and influence on the expressions of omentin-1 and Ang-2

doi:10.3760/cma.j.issn.1673422X.2018.02.006

Abstract

Abstract: ObjectiveTo explore the curative effect of stereotactic radiotherapy combined with transcatheter arterial chemoembolization (TACE) for patients with hepatic metastases of colorectal cancer and influence on the expressions of omentin1 and angiopoietin2 (Ang2). MethodsA total of 90 patients with hepatic metastases of colorectal cancer from December 2013 to December 2015 in our hospital were selected as the research objects. Patients were divided into observation group and control group according to random number table method with 45 cases respectively. Patients in control group were treated with TACE, and patients in observation group were treated with stereotactic radiotherapy combined with TACE. After treatment, the clinical efficacy, expression levels of plasma omentin1 and Ang2, score of quality of life and adverse reaction were compared in the two groups. ResultsThe objective response rate in observation group (82.2%) was significantly higher than that in control group (60.0%), and the difference was statistically significant (χ2=5.409, P=0.020). After treatment, the omentin1 and Ang2 expression levels in observation group were lower than those in control group ［(43.7±18.1) ng/ml vs. (52.1±17.9) ng/ml, t=2.214, P=0.029; (2.0±0.2) g/L vs. (2.3±0.3) g/L, t=6.028, P＜0.001］. The score of quality of life in observation group was significantly higher than that in control group ［(87.6±11.2) vs. (68.7±10.3)］, and the difference was statistically significant (t=8.332, P＜0.001). There were no differences on the adverse reaction rates such as abnormal liver function (35.6% vs. 42.2%, χ2=0.421, P=0.517), nausea and vomiting (44.4% vs. 37.8%, χ2=0.413, P=0.520), skin injury (6.7% vs. 0, χ2=3.101, P=0.078) and fever (35.6% vs. 31.1%, χ2=0.202, P=0.655) between the two groups. ConclusionThe implementation of stereotactic radiotherapy combined with TACE in the treatment of hepatic metastases of colorectal cancer is a safety and effective method. It can significantly reduce the expression levels of plasma omentin1 and Ang2, inhibit of tumor angiogenesis, and improve the quality of life of patients.

Key words: Colorectal neoplasms, Radiosurgery, Transcatheter arterial chemoembolization, Angiopoietin-2, Omentin-1

DU Wei-Guang. Curative effect of stereotactic radiotherapy combined with TACE for patients with hepatic metastases of colorectal cancer and influence on the expressions of omentin-1 and Ang-2[J]. Journal of International Oncology, 2018, 45(2): 87-91.

References

［1］ Ballantyne GH, Quin J. Surgical treatment of liver metastases in patients with colorectal cancer［J］. Cancer, 1993, 71(12 Suppl): 42524266. ［2］冯字清, 苏加利, 蔡薇薇, 等. TACE联合体部伽玛刀放疗与手术治疗大肠癌肝转移的疗效比较［J］. 医学临床研究, 2017, 34(1): 166168. DOI: 10.3969/j.issn.16717171.2017.01.061. ［3］ Chen WJ, Yuan SF, Zhu LJ, et al. Threedimensional conformal radiotherapy in combination with transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma［J］. J BUON, 2014, 19(3): 692697. ［4］ Hu X, Feng F, Li X, et al. Gene polymorphisms related to insulin resistance and geneenvironment interaction in colorectal cancer risk［J］. Ann Hum Biol, 2015, 42(6): 560568. DOI: 10.3109/03014460.2014.1002532. ［5］ Zhang JH, Wang LH, Li XJ, et al. Expression of Ang2/Tie2 and PI3K/AKT in colorectal cancer［J］. Asian Pac J Cancer Prev, 2014, 15(20): 86518656. ［6］ Aleksandrova K, Di Giuseppe R, Isermann B, et al. Circulating omentin as a novel biomarker for colorectal cancer risk: data from the EPICPotsdam cohort study［J］. Cancer Res, 2016, 76(13): 38623871. DOI: 10.1158/00085472.CAN153464. ［7］ Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making［J］. Ann Oncol, 2012, 23(10): 24792516. DOI: 10.1093/annonc/mds236. ［8］ Benson AB, BekaiiSaab T, Chan E, et al. Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines［J］. J Natl Compr Canc Netw, 2013, 11(5): 519528. ［9］ Gralla RJ. Qualityoflife evaluation in cancer: the past and the future［J］. Cancer, 2015, 121(24): 42764278. DOI: 10.1002/cncr.29680. ［10］ Dagoglu N, Mahadevan A, Nedea E, et al. Stereotactic body radiotherapy (SBRT) reirradiation for pelvic recurrence from colorectal cancer［J］. J Surg Oncol, 2015, 111(4): 478482. DOI: 10.1002/jso.23858. ［11］ GonzálezVacarezza N, Alonso I, Arroyo G, et al. Predictive biomarkers candidates for patients with metastatic colorectal cancer treated with bevacizumabcontaining regimen［J］. Drug Metab Pers Ther, 2016, 31(2): 8390. DOI: 10.1515/dmpt20150027. ［12］ Hong S, Jung HI, Ahn TS, et al. Expressions and clinical significances of angiopoietin1, angiopoietin2, and Tie2 receptor in patients with colorectal cancer［J］. Ann Coloproctol, 2017, 33(1): 915. DOI: 10.3393/ac.2017.33.1.9. ［13］ Baek MJ, Jeong D, Kim CJ, et al. Abstract 33: in vitro functional study of Ang 2 in colorectal cancer cell line and the significance of Ang 2 expression in colorectal cancer patients［J］. Cancer Res, 2014, 74(19 Suppl): 33. ［14］ Jung SY, Sobel EM, Papp JC, et al. Effect of genetic variants and traits related to glucose metabolism and their interaction with obesity on breast and colorectal cancer risk among postmenopausal women［J］. BMC Cancer, 2017, 17(1): 290. DOI: 10.1186/s1288501732847. ［15］陈燕, 赵晓彤, 陈明卫, 等. 血浆网膜素1水平与结直肠癌的相关性研究［J］. 安徽医科大学学报, 2015, 50(1): 7577.

[1]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[2]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[3]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[4]	Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222.
[5]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[6]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues [J]. Journal of International Oncology, 2023, 50(8): 470-474.
[7]	Chen Zhuo, Tao Jun, Chen Lin, Ke Jing. Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer [J]. Journal of International Oncology, 2023, 50(5): 268-273.
[8]	Zhao Yongrui, Gao Ying, Chen Yidong, Xu Jiankun. Efficacy and safety of linear accelerator-based fractionated stereotactic radiotherapy for small volume brain metastases [J]. Journal of International Oncology, 2023, 50(3): 138-143.
[9]	Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun. Construction of postoperative prognosis model for patients with colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 157-163.
[10]	Xu Liangfu, Li Yuanfei. Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 186-190.
[11]	Liu Yujie, Zhao Zhiqiang, Wang Zicheng. Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer [J]. Journal of International Oncology, 2023, 50(12): 717-722.
[12]	Tao Hong, Yin Hong, Luo Hong, Tao Jiayu. Potential strategies for targeting tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors for colorectal cancer [J]. Journal of International Oncology, 2023, 50(11): 683-687.
[13]	Wang Xi, Wu Chuanqing. Research progress in reversing multidrug resistance in colorectal cancer [J]. Journal of International Oncology, 2023, 50(1): 42-46.
[14]	Gao Yizhao, Liu Yang, Liu Qiulong, Xing Jinliang. Application of circulating cell-free nucleic acid in clinical diagnosis and treatment of colorectal cancer [J]. Journal of International Oncology, 2022, 49(9): 555-559.
[15]	He Zhefeng, Wu Yiyang, Li Zhenjun, Ying Xiaojiang. Predictive value of inflammatory markers in colorectal cancer [J]. Journal of International Oncology, 2022, 49(9): 560-563.